Intercept Pharmaceuticals Priced, Nasdaq: ICPT
Developing novel synthetic therapeutics for chronic liver diseases.
Industry: Health Care
First Day Return: +29.3%
ICPT
Developing novel synthetic therapeutics for chronic liver diseases.
| IPO Data | |
|---|---|
| IPO Date | 10/10/2012 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $75 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | New York, NY, United States |
| Founded | 2002 |
| Employees at IPO | 18 |
| Website www.interceptpharma.com | |
IPO News for Intercept Pharmaceuticals
Intercept Pharmaceuticals (ICPT) Performance
